Digital Health
HATCo will spend a total of $550 million in capital funding to invest in technologies and innovation.
The guidance aims to help countries move toward healthcare digitization through a person-centered point of service system.
The behavioral health company's Engage platform will be available to existing commercial fully insured, self-funded members on an opt-in basis and via Sentara's Marketplace membership.
The company also reported Q3 2024 earnings, noting total revenue of $76.4 million, adjusted EBITDA of $7.3 million and a net loss of $14.7 million.
The acquisition includes all of NeuroReality's assets, including its flagship rehabilitation product, Koji's Quest.
The company will use the funds to expand in Asian and U.S. markets, advance its AI algorithms and grow its workforce.
The funding will support clinical trials for the company's NeuroHawk brain-scanning device.
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
The company offers a marketplace for individuals seeking addiction and mental health treatment. It will use the funds to scale its workforce and expand its reach.
The aim is to attract government and healthcare experts who can gain a better understanding of digitalization in healthcare.